Endocrine therapy in early-stage estrogen Receptor-Low breast cancer: a systematic review and Meta-Analysis

Clicks: 24
ID: 325577
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #218 of 414 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 414 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Tumors with ≥1% estrogen receptor (ER) expression by immunohistochemistry (IHC) are classified as hormone receptor-positive. While this definition includes ER-low tumors (ER 1-9%), the clinical benefit of endocrine therapy (ET) in ER-low early-stage breast cancer (BC) remains uncertain. METHODS: This is a systematic review and meta-analysis of studies in early-stage ER-positive, HER2-negative BC reporting (i) ET efficacy within ER-low tumors and/or (ii) outcomes comparing ER-low versus ER-rich disease. Ovid MEDLINE, Embase, and conference abstracts were searched through January 2025. Endpoints were disease-free survival (DFS) and overall survival (OS). Random-effects meta-analyses were performed to derive pooled hazard ratios (HRs) with 95% confidence intervals (95% CI). Heterogeneity was assessed with the I² statistic. RESULTS: Of 8,982 records screened, 17 studies were included, comprising 10,232 patients with ER-low tumors and 58,662 with ER-rich disease. Among the ER-low group, receipt of ET was associated with a reduction of 33% in the risk of relapse or death (HR 0.67, 95% CI 0.54-0.85, I²=0%) and of 22% in the risk of death (HR 0.78, 95% CI 0.68-0.90; I²=19.2%). Compared with ER-rich disease, ER-low tumors had inferior outcomes for both DFS (HR 2.18, 95% CI 1.58-3.00; I²=78%) and OS (HR 2.08, 95% CI 1.30-3.31; I²=95.8%). CONCLUSIONS: In patients with ER-low tumors, ET use was associated with improved outcomes. These findings support consideration of ET in early-stage ER-low disease and the inclusion of these patients in trials evaluating novel ET-based therapies, alongside therapeutic approaches appropriate to their higher baseline risk of relapse.
Reference Key
openalex_W7203731375 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Davide Massa, Edoardo Chiappe, Virginia Delucchi, Fabio Girardi, Eva Blondeaux, Marina La Commare, Valentina Guarneri, Matteo Lambertini, Maria Vittoria Dieci
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag281
URL
https://doi.org/10.1093/jnci/djag281
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.